Non-healing Wound
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Angeles TherapeuticsCA - Los Angeles
1 program1
CeFAZolin Injectable SolutionPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
2027
2028
Angeles TherapeuticsCeFAZolin Injectable Solution
OmezaOmeza Products Used in Combination
Clinical Trials (2)
Total enrollment: 171 patients across 2 trials
Antibiotic Tumescent For Chronic Wounds
Start: May 2024Est. completion: May 202860 patients
Phase 2Recruiting
Omeza Combination Therapy for the Management and Treatment of Chronic Cutaneous Wounds/Ulcers of Multiple Etiologies
Start: Jul 2022Est. completion: May 2024111 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 171 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.